| Appeal Launched Over Ruling That Arzerra Did Not Infringe Genentech and Biogen Idec US Patent Covering Methods of Treating CLL With Anti-CD20 Antibodies COPENHAGEN, Denmark, Dec. 6, 2011 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced today that Genentech and Biogen Idec have appealed the judgment in favor of GlaxoSmithKline (GSK) in a patent infringement case involving Arzerra brought against GSK by Genentech and Biogen Idec. The two companies have appealed to the U.S. Court of Appeals...continued GNMSF GNMSY |
Tuesday, December 6, 2011
Genmab Announces Appeal of US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment